Antonio Cannata | Myocarditis | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Best Researcher Award

Antonio Cannatà
King’s College London, United Kingdom

Antonio Cannatà
Affiliation King’s College London
Country United Kingdom
Scopus ID 56950331100
Documents 171
Citations 3,927
h-index 32
Subject Area Myocarditis & Cardiovascular Medicine
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID 0000-0001-7609-6297

Antonio Cannatà is a cardiovascular researcher affiliated with King’s College London whose scholarly work focuses on heart failure, myocarditis, cardio-kidney-metabolic disorders, and evidence-based cardiovascular medicine. His peer-reviewed publications demonstrate continued contributions to understanding disease progression, clinical outcomes, and guideline development for patients with complex cardiovascular conditions. Through multidisciplinary collaborations and international research initiatives, his publications support improved diagnosis, risk assessment, and therapeutic decision-making in modern cardiology.[1]

Abstract

Antonio Cannatà’s research focuses on cardiovascular medicine, particularly heart failure, myocarditis, and cardio-kidney-metabolic disorders. His publications integrate clinical investigation, multicentre collaboration, and translational research to improve understanding of disease mechanisms, prognosis, and patient management. His studies support international cardiovascular research through evidence on myocarditis, sudden cardiac death, and heart failure guidelines.

Keywords

Cardiology, Heart Failure, Myocarditis, Cardiovascular Medicine, Clinical Research, Cardio-Kidney-Metabolic Disease, Evidence-Based Medicine, Medical Guidelines, Translational Medicine, Cardiovascular Outcomes.

Introduction

Cardiovascular diseases remain a leading global health challenge, requiring advances in diagnosis, prevention, and treatment. Antonio Cannatà contributes through collaborative research on myocarditis, heart failure, and complex cardiovascular disorders. His publications translate clinical evidence into improved patient care while supporting guideline development and fostering international scientific collaboration.[2]

Research Profile

Based at King’s College London, Antonio Cannatà has established a multidisciplinary research profile in cardiovascular medicine. His Scopus metrics, including an h-index of 32 and over 3,900 citations, reflect sustained scholarly impact. His work spans observational studies, clinical investigations, and consensus documents addressing disease progression, risk stratification, and evidence-based cardiovascular care.[1]

Research Contributions

  • Advanced understanding of recurrent myocarditis through multicentre international clinical investigations.
  • Contributed to expert consensus recommendations supporting heart failure management in resource-limited healthcare environments.
  • Investigated sudden death risk in cardio-kidney-metabolic patients using contemporary cardiovascular evidence.
  • Supported collaborative cardiovascular research integrating clinical outcomes with guideline development.

Publications

  • Sudden Death in Cardio-Kidney-Metabolic Patients. JACC (2026).
    DOI: 10.1016/j.jacc.2026.05.031
  • Bridging the Gap: Adapting Heart Failure Guidelines for Resource-Limited Settings. European Journal of Heart Failure (2026). DOI: 10.1093/ejhf/xuag142
  • Insights Into the Natural History of Recurrent Myocarditis. Journal of the American Heart Association (2026). DOI: 10.1161/JAHA.125.046767

Research Impact

Antonio Cannatà’s research advances cardiovascular medicine through clinical studies, evidence synthesis, and guideline development. His publications on myocarditis, heart failure, and cardio-kidney-metabolic disorders enhance understanding of disease management and patient outcomes. His h-index, citation impact, and multidisciplinary collaborations demonstrate sustained scholarly influence and clinical relevance. [1]

Award Suitability

Antonio Cannatà demonstrates research excellence through sustained contributions to cardiovascular medicine. His publications, citation impact, and multinational collaborations have advanced knowledge in myocarditis, heart failure, cardiovascular risk, and clinical guidelines. His rigorous, collaborative scholarship and clinically relevant research align with the objectives of the Best Researcher Award. [2]

Conclusion

Antonio Cannatà has established a distinguished academic profile through sustained contributions to cardiovascular medicine. His research on myocarditis, heart failure, and cardio-kidney-metabolic disease advances patient care and scientific understanding. His publication record, citation impact, and collaborative research demonstrate lasting contributions to cardiovascular science, interdisciplinary innovation, and evidence-based healthcare.

References

  1. Elsevier. (n.d.). Scopus author details: Antonio Cannatà, Author ID 56950331100. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56950331100
  2. Cannatà A., et al. (2026). Sudden Death in Cardio-Kidney-Metabolic Patients. JACC.
    DOI: https://doi.org/10.1016/j.jacc.2026.05.031
  3. Abdin A., Aktaa S., Cannatà A., et al. (2026). Bridging the Gap: Adapting Heart Failure Guidelines for Resource-Limited Settings. European Journal of Heart Failure.
    DOI: https://doi.org/10.1093/ejhf/xuag142
  4. Baggio C., Cannatà A., et al. (2026). Insights Into the Natural History of Recurrent Myocarditis, A Multicenter International Study. Journal of the American Heart Association.
    DOI: https://doi.org/10.1161/JAHA.125.046767

Rebecca Neiberg | Cardiovascular Researches | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Best Researcher Award

Rebecca Neiberg
Wake Forest University, United States

Rebecca Neiberg
Affiliation Wake Forest University
Country United States
Scopus ID 15842082400
Documents 100
Citations 4,364
h-index 35
Subject Area Cardiovascular Researches
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID 0000-0003-0719-6520

Rebecca Neiberg is a researcher at Wake Forest University whose scholarly work has contributed significantly to cardiovascular health, aging research, obesity, diabetes, and clinical biostatistics. Her publications emphasize evidence-based approaches for evaluating lifestyle interventions, long-term health outcomes, and chronic disease management. Through multidisciplinary collaborations, her research supports improvements in preventive medicine, healthy aging, and cardiovascular risk assessment while providing statistically rigorous analyses for large clinical studies.[1]

Abstract

Rebecca Neiberg’s research portfolio encompasses cardiovascular medicine, obesity, diabetes, gerontology, and statistical methodology. Her collaborative investigations evaluate dietary interventions, physical function, disability prevention, and metabolic outcomes in aging populations. These contributions provide valuable evidence supporting clinical decision-making and public health strategies for chronic disease prevention.[1]

Keywords

Cardiovascular Research, Healthy Aging, Diabetes, Obesity, Clinical Trials, Biostatistics, Lifestyle Intervention, Gerontology, Metabolic Health, Preventive Medicine.

Introduction

The increasing prevalence of cardiovascular disease and metabolic disorders highlights the importance of high-quality clinical research. Rebecca Neiberg has participated in large collaborative studies investigating lifestyle modification, caloric restriction, weight management, and long-term functional health among older adults. Her analytical expertise contributes to reliable interpretation of clinical outcomes.[2]

Research Profile

According to the supplied academic profile, Rebecca Neiberg has accumulated 4,364 citations with an h-index of 35. Her research emphasizes longitudinal clinical studies, advanced statistical analyses, cardiovascular outcomes, diabetes management, obesity interventions, and aging-related health research through collaborative, multidisciplinary investigations.[1]

Research Contributions

Recent publications examine caloric restriction with time-restricted eating in older adults, long-term disability outcomes following the Look AHEAD clinical trial, and relationships between adiposity reduction, HbA1c improvement, and insulin use. These studies enhance understanding of cardiovascular risk reduction and healthy aging through evidence-based interventions.[2]

Publications

  • Caloric restriction and time-restricted eating in older adults with overweight or obesity (2026).
  • Late-life disability following the Action for Health in Diabetes (Look AHEAD) trial (2026).
  • Associations between decreases in adiposity and reductions in HbA1c and insulin use in the Look AHEAD cohort (2025).

Research Impact

The combination of extensive citation impact, sustained publication record, and participation in influential multicenter clinical studies demonstrates meaningful contributions to cardiovascular and aging research. Her work supports clinicians, researchers, and healthcare policymakers seeking evidence for effective chronic disease management.[1]

Award Suitability

Rebecca Neiberg’s sustained scholarly productivity, high citation record, and collaborative leadership in cardiovascular, obesity, and aging research align well with the objectives of the International Research Awards on Cardiology & Cardiovascular Medicine, recognizing impactful scientific achievement and excellence in translational health research.[1]

Conclusion

Rebecca Neiberg has established a distinguished research profile through rigorous statistical analysis, collaborative clinical investigation, and evidence-based studies addressing cardiovascular health and healthy aging. Her contributions continue to strengthen scientific understanding of lifestyle interventions and long-term health outcomes in aging populations.[2]

External Links

References

  1. Elsevier. (n.d.). Scopus author details: Rebecca Neiberg, Author ID 15842082400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=15842082400
  2. Houston DK, Fanning J, Nicklas BJ, et al. Caloric restriction and time-restricted eating in older adults with overweight or obesity. The Journals of Gerontology: Series A (2026).
    DOI: https://doi.org/10.1093/gerona/glag061
  3. Semelka CT, Neiberg RH, Haynie HD, et al. Late-life disability following the Action for Health in Diabetes (Look AHEAD) trial. The Journals of Gerontology: Series A (2026).
    DOI: https://doi.org/10.1093/gerona/glaf245

Murimisi Mukansi | Cardiovascular Researches | Research Excellence Award

Published on by Cardiology and Cardiovascular Medicine

Research Excellence Award

Murimisi Mukansi
University of The Witwatersrand, South Africa

Murimisi Mukansi
Affiliation University of The Witwatersrand
Country South Africa
Scopus ID 56659430900
Documents 7
Citations 170
h-index 5
Subject Area Cardiovascular Researches
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID 0000-0002-7013-9070

Murimisi Mukansi is a researcher at the University of The Witwatersrand whose academic interests encompass cardiovascular medicine, infectious diseases, pulmonary disorders, and biomarker-based clinical investigations. His published work demonstrates an evidence-based approach to understanding disease mechanisms and improving patient management through translational medical research. With an established Scopus profile, consistent citation record, and growing international visibility, his contributions support advances in cardiovascular science and clinical medicine while promoting interdisciplinary collaboration between laboratory investigation and patient-centered healthcare.[1]

Abstract

The research activities of Murimisi Mukansi focus on cardiovascular complications associated with infectious diseases, particularly pneumonia and COVID-19. His investigations evaluate clinical manifestations, cardiac biomarker responses, and disease severity to strengthen diagnostic accuracy and improve patient outcomes. The published findings contribute to evidence-based cardiovascular medicine and interdisciplinary clinical research.[2]

Keywords

Cardiovascular Medicine, COVID-19, Community-Acquired Pneumonia, Cardiac Biomarkers, Clinical Research, Translational Medicine, Infectious Diseases, Medical Diagnostics.

Introduction

Modern cardiovascular medicine increasingly recognizes the influence of infectious diseases on cardiac health. Investigating biomarker profiles, inflammatory responses, and clinical outcomes provides valuable evidence for optimizing diagnosis and treatment. Research in this area supports improved management of patients presenting with complex cardiopulmonary conditions.[2]

Research Profile

Murimisi Mukansi has established an academic profile through publications in peer-reviewed medical journals, supported by 170 citations and an h-index of 5. His work demonstrates expertise in cardiovascular investigations, infectious disease pathology, biomarker evaluation, and collaborative clinical research that addresses contemporary healthcare challenges.[1]

Research Contributions

His recent publication examining clinical characteristics and cardiac biomarker elevation among patients with community-acquired pneumonia and COVID-19 pneumonia provides comparative evidence supporting cardiovascular risk assessment in infectious diseases. Such studies contribute to improved clinical interpretation, patient stratification, and therapeutic decision-making.[2]

Publications

  • Distinct Patterns of Clinical Features and Cardiac Biomarker Elevation in Community-Acquired Pneumonia and COVID-19 Pneumonia. Pathogens, 2026.

Research Impact

The research contributes to a broader understanding of cardiovascular complications associated with respiratory infections. By integrating biomarker analysis with clinical observations, the findings support precision medicine, improved patient monitoring, and evidence-informed healthcare strategies for complex infectious diseases.[2]

Award Suitability

Murimisi Mukansi demonstrates qualities consistent with recognition through the International Research Awards on Cardiology & Cardiovascular Medicine. His scholarly contributions, publication quality, interdisciplinary collaborations, and focus on clinically relevant cardiovascular research illustrate scientific excellence and meaningful impact within contemporary medical research.

Conclusion

Murimisi Mukansi has developed a research portfolio centered on cardiovascular complications arising from infectious diseases. His work strengthens understanding of disease mechanisms, supports improved diagnostic practice, and contributes valuable evidence for clinicians and researchers seeking to enhance patient care through translational cardiovascular science.

References

  1. Elsevier. (n.d.). Scopus author details: Murimisi Mukansi, Author ID 56659430900. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56659430900
  2. Mukansi, M., Steel, H. C., Rossouw, T. M., et al. (2026). Distinct Patterns of Clinical Features and Cardiac Biomarker Elevation in Community-Acquired Pneumonia and COVID-19 Pneumonia. Pathogens.
    DOI: https://doi.org/10.3390/pathogens15070676

Zhi-Hui Zhu | Cardiovascular Researches | Innovative Research Award

Published on by Cardiology and Cardiovascular Medicine

Innovative Research Award

Zhi-Hui Zhu
Zhejiang University, China
Zhi-Hui Zhu
Affiliation Zhejiang University
Country China
Scopus ID 57199280440
Documents 4
Citations 73
h-index 3
Subject Area Cardiovascular Researches
Event International Research Awards on Cardiology & Cardiovascular Medicine

The Innovative Research Award recognizes scholarly achievements that have contributed to the advancement of biomedical and life science research. Zhi-Hui Zhu of Zhejiang University has developed a research profile characterized by investigations into liver development, regenerative biology, molecular genetics, and experimental disease modeling. Through studies employing zebrafish and mammalian systems, Zhu has contributed to understanding developmental regulation, tissue regeneration, and cellular lineage mechanisms relevant to human health and disease.[1] The body of work demonstrates interdisciplinary integration of genetics, developmental biology, and translational biomedical research, providing a foundation for future applications in regenerative medicine and cardiovascular-related biological investigations.[2]

Abstract

This article summarizes the scientific contributions of Zhi-Hui Zhu in developmental biology and regenerative research. The documented publications explore liver organogenesis, gene regulation, tissue regeneration, and transgenic model development. Collectively, these studies have contributed to understanding molecular pathways that govern organ formation and repair, providing insights applicable to broader biomedical and cardiovascular research contexts.[3]

Keywords

Developmental biology; Regenerative medicine; Zebrafish genetics; Liver development; Molecular signaling; Tissue regeneration; Functional genomics; Biomedical research.

Introduction

Modern biomedical research increasingly relies on model organisms to uncover mechanisms underlying organ development and disease progression. Zhu’s investigations have focused on genetic and cellular pathways involved in liver biology, utilizing zebrafish and mammalian systems to evaluate developmental processes and regenerative responses. These studies provide mechanistic evidence supporting the role of specific genes and signaling networks in maintaining tissue integrity and recovery following injury.[1][3]

Research Profile

Affiliated with Zhejiang University, Zhi-Hui Zhu has authored and co-authored peer-reviewed publications indexed in major scientific databases. The available metrics indicate four indexed documents, seventy-three citations, and an h-index of three. Research themes encompass developmental genetics, liver biology, transgenic technologies, and regenerative mechanisms, reflecting a consistent commitment to experimentally driven biological inquiry.[1]

Research Contributions

Among Zhu’s notable contributions is the characterization of liver-enriched gene family members essential for normal liver development in zebrafish, expanding knowledge of organogenesis and developmental regulation.[2] Additional investigations examined expression patterns of homologous genes in mammalian systems, providing comparative biological insights.[3] Research on Def haploinsufficiency demonstrated activation of p53-dependent TGFβ signaling during regenerative responses, revealing mechanisms associated with scar formation following partial hepatectomy.[4] Zhu also contributed to transgenic zebrafish methodologies supporting functional genomic analysis of candidate genes involved in tumor pathogenesis.[5]

Publications

  • Chang CQ et al. (2011). Liver-enriched gene 1a and 1b encode novel secretory proteins essential for normal liver development in zebrafish.
  • Zhu ZH et al. (2012). Analysis of expression pattern of zebrafish leg1 homologous gene mu-leg1 in mouse.
  • Zhu ZH et al. (2014). Haploinsufficiency of Def activates p53-dependent TGFβ signalling and causes scar formation after partial hepatectomy.
  • Ung CY et al. (2015). Mosaic zebrafish transgenesis for functional genomic analysis of cooperative genes in tumor pathogenesis.
  • Gao C et al. (2018). Hepatocytes in a normal adult liver are derived solely from embryonic hepatocytes.

Research Impact

The research portfolio has contributed valuable evidence regarding developmental pathways, tissue regeneration, and cellular lineage tracing. These findings support broader scientific efforts aimed at understanding disease mechanisms and regenerative therapies. The citation record further indicates continued scholarly engagement with the published findings, particularly in developmental and translational biology disciplines.[1][6]

Award Suitability

Zhu’s record demonstrates sustained contributions to biological research through original investigations, methodological development, and collaborative scientific output. The integration of developmental genetics and regenerative biology aligns with the objectives of the International Research Awards on Cardiology & Cardiovascular Medicine, particularly where fundamental biological discoveries inform future therapeutic and translational applications.[5]

Conclusion

Zhi-Hui Zhu’s scholarly contributions reflect a focused research trajectory in developmental and regenerative biology. Through investigations involving gene regulation, organ development, and cellular regeneration, the researcher has advanced scientific understanding of biological processes relevant to health and disease. The documented body of work provides a credible basis for recognition through an academic research award program.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Zhi-Hui Zhu, Author ID 57199280440. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57199280440
  2. Chang CQ, Hu MJ, Zhu ZH, et al. (2011). Liver-enriched gene 1a and 1b Encode Novel Secretory Proteins Essential for Normal Liver Development in Zebrafish. PLoS ONE.
    https://doi.org/10.1371/journal.pone.0022910
  3. Zhu ZH, Hu MJ, Chang CQ, Peng JR. (2012). Analysis of expression pattern of zebrafish leg1 homologous gene mu-leg1 in mouse. Hereditas.
  4. Zhu ZH, Chen J, Xiong JW, Peng JR. (2014). Haploinsufficiency of Def Activates p53-Dependent TGFβ Signalling and Causes Scar Formation after Partial Hepatectomy. PLoS ONE.
    https://doi.org/10.1371/journal.pone.0096576
  5. Ung CY, Guo F, Zhang X, Zhu Z, Zhu S. (2015). Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis. Journal of Visualized Experiments.
    https://doi.org/10.3791/52567
  6. Gao C, Zhu Z, Gao Y, et al. (2018). Hepatocytes in a Normal Adult Liver Are Derived Solely from the Embryonic Hepatocytes. Journal of Genetics and Genomics.
    https://doi.org/10.1016/j.jgg.2017.12.003

Ersilia Nigro | Cardiovascular Researches | Innovative Research Award

Published on by Cardiology and Cardiovascular Medicine

Innovative Research Award

Ersilia Nigro
Università della Campania Vanvitelli, Italy

Ersilia Nigro
Affiliation Università della Campania Vanvitelli
Country Italy
Scopus ID 57194323816
Documents 119
Citations 3,964
h-index 33
Subject Area Cardiovascular Researches
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID 0000-0001-5637-1685

The Innovative Research Award recognizes the scholarly contributions of Ersilia Nigro, an Italian researcher affiliated with Università della Campania Vanvitelli, whose work has advanced knowledge in cardiovascular and metabolic sciences. Her interdisciplinary research explores adipokines, inflammatory biomarkers, exercise physiology, metabolic dysfunction, and lifestyle-related determinants of cardiovascular health. With an established publication record, a Scopus h-index of 33, and nearly four thousand citations, her investigations have contributed to translational approaches linking molecular mechanisms with clinical practice.[1]

Abstract

This article summarizes the scientific profile of Ersilia Nigro in relation to the Innovative Research Award. Her work integrates molecular cardiology, metabolism, and preventive medicine, emphasizing biomarkers associated with obesity, inflammation, exercise adaptation, and cardiovascular risk. Current research demonstrates sustained engagement with emerging topics including adiponectin signaling, orexin regulation, muscle wasting, and cardiometabolic interventions.[2]

Keywords

Cardiovascular research; adipokines; exercise physiology; obesity; inflammation; cardiometabolic health; translational medicine; biomarkers.

Introduction

Contemporary cardiovascular science increasingly relies on multidisciplinary investigations connecting lifestyle behaviors with molecular pathways. Nigro’s research addresses this need by examining how exercise, nutrition, sleep, and metabolic dysfunction influence cardiovascular outcomes and chronic disease progression.[3]

Research Profile

Her publication portfolio spans clinical, translational, and experimental studies. Indexed in Scopus with 119 documents and 3,964 citations, her scholarship demonstrates sustained influence across cardiovascular medicine, endocrinology, and metabolic research. Collaborative investigations frequently examine biomarker-driven approaches to patient stratification and disease management.[1]

Research Contributions

  • Investigation of adiponectin isoforms and inflammatory biomarkers in chronic diseases.
  • Evaluation of exercise interventions and their effects on cardiometabolic health.
  • Analysis of lifestyle factors, including sleep and nutrition, in cardiovascular regulation.
  • Research on muscle wasting, dyslipidemia, and patient management strategies in chronic respiratory disorders.

Publications

Recent publications include studies on irisin responses in obese middle-aged males, exercise-induced modulation of adiponectin, orexin and lifestyle habits, COPD-associated muscle wasting, and inflammatory markers in Crohn’s disease.[4]

Research Impact

The impact of Nigro’s work is reflected in extensive citation activity and the adoption of biomarker-based approaches within cardiometabolic research. Her studies support evidence-informed strategies for prevention, risk assessment, and personalized interventions targeting obesity-related cardiovascular conditions.[5]

Award Suitability

The Innovative Research Award acknowledges scientific originality, interdisciplinary collaboration, and measurable influence. Nigro’s sustained contributions across cardiovascular medicine, molecular biology, and preventive health align with these criteria through a record of peer-reviewed outputs, translational relevance, and international visibility.[6]

Conclusion

Ersilia Nigro has established a significant research profile at the intersection of cardiovascular science and metabolism. Her investigations continue to inform understanding of biomolecular pathways underlying cardiometabolic disorders while advancing preventive and therapeutic perspectives relevant to contemporary healthcare challenges.

References

  1. Elsevier. (n.d.). Scopus author details: Ersilia Nigro, Author ID 57194323816. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57194323816
  2. Nigro, E., et al. (2026). Effects of Two Different Training Programs on Cardiometabolic Health, Body Composition and Irisin in Middle Age Obese Males: A Pilot Study. Life.
    DOI: https://doi.org/10.3390/life16040657
  3. Nigro, E., et al. (2025). Orexin and Lifestyle Habits: A Meaningful Connection Among Nutrition, Physical Activity, and Sleep Pattern in Health and Diseases. International Journal of Molecular Sciences.
    DOI: https://doi.org/10.3390/ijms26188980
  4. Nigro, E., et al. (2026). Acute Resistance Exercise Temporarily Reduces Circulating Adiponectin in Trained Young Men: A Pilot Study. Biomolecules. DOI: https://doi.org/10.3390/biom16020229
  5. Nigro, E., et al. (2025). Muscle Wasting and Treatment of Dyslipidemia in COPD: Implications for Patient Management. Biomedicines.
    DOI: https://doi.org/10.3390/biomedicines13081817
  6. Nigro, E., et al. (2025). Adiponectin and HMW Oligomers in Relation to Inflammatory Markers in Crohn’s Disease Patients. Biomedicines.
    DOI: https://doi.org/10.3390/biomedicines13020273

Bart Meuris | Cardiac Devices and Implants | Innovative Research Award

Published on by Cardiology and Cardiovascular Medicine

Innovative Research Award

Bart Meuris
University Hospitals Leuven, Belgium

Bart Meuris
Affiliation University Hospitals Leuven
Country Belgium
Scopus ID 6602378855
Documents 208
Citations 7,574
h-index 37
Subject Area Cardiac Devices and Implants
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID 0000-0001-9176-293X

Bart Meuris is a Belgian cardiovascular researcher, cardiac surgeon, and academic leader associated with University Hospitals Leuven and the Department of Cardiovascular Sciences. His scholarly work focuses on cardiac surgery, heart valve technologies, transcatheter interventions, cardiovascular biomaterials, and mechanical circulatory support systems. Through an extensive publication portfolio and sustained contributions to cardiovascular innovation, Meuris has played a significant role in advancing clinical and translational research within the field of cardiac devices and implants.[1]

Abstract

Bart Meuris has established a distinguished academic record in cardiovascular medicine through research addressing heart valve replacement, transcatheter therapies, surgical innovation, thrombosis prevention, and device performance evaluation. His work integrates engineering principles with clinical practice to improve patient outcomes in structural heart disease. With more than two hundred indexed publications and thousands of citations, his research demonstrates substantial influence within contemporary cardiovascular science.[1]

Keywords

Cardiac Surgery, Heart Valve Replacement, Transcatheter Aortic Valve Implantation, Cardiovascular Devices, Valve Durability, Mechanical Valve Thrombosis, Cardiovascular Innovation, Structural Heart Disease.

Introduction

The development of safer and more durable cardiovascular devices remains a major priority in modern medicine. Bart Meuris has contributed to this objective through investigations of surgical and transcatheter valve technologies, device-related complications, and long-term cardiovascular outcomes. His work reflects a multidisciplinary approach that combines clinical evidence, biomedical engineering, and translational research to address complex cardiovascular challenges.[2]

Research Profile

As Chair within the Department of Cardiovascular Sciences at Universitair Ziekenhuis Leuven, Meuris has maintained active involvement in research concerning prosthetic heart valves, cardiovascular surgery, hemodynamics, and implant performance assessment. His scholarly output spans clinical studies, registry analyses, experimental investigations, and collaborative international projects. The breadth of his publication record reflects sustained engagement with emerging cardiovascular technologies and evidence-based treatment strategies.[3]

Research Contributions

  • Investigated Factor XI inhibition strategies for preventing mechanical valve thrombosis in experimental models.[4]
  • Evaluated sex-related outcomes following sutureless aortic valve replacement using registry-based evidence.[5]
  • Examined the current status and future development of rapid deployment valve technologies.[6]
  • Studied durability and hemodynamic performance of transcatheter valves used in aortic stenosis treatment.[7]

Publications

Recent publications authored or co-authored by Meuris include studies on Factor XI inhibition for mechanical valve thrombosis prevention, sex-related outcomes following Perceval Plus valve replacement, rapid deployment valve technologies, transcatheter valve durability, and cerebrovascular complications following transcatheter aortic valve implantation. These works collectively address clinical efficacy, procedural safety, and long-term device performance.[4][7]

Research Impact

The measurable influence of Meuris’s research is reflected by an h-index of 37, more than 7,500 citations, and a substantial body of peer-reviewed publications. His investigations have contributed to understanding cardiovascular device performance, surgical outcomes, and thrombosis prevention strategies, supporting evidence-based advancements in cardiovascular medicine and cardiac surgery.[1]

Award Suitability

Bart Meuris demonstrates qualifications aligned with the objectives of the International Research Awards on Cardiology & Cardiovascular Medicine. His sustained publication record, leadership within cardiovascular sciences, and contributions to cardiac device innovation illustrate a commitment to advancing clinical research and improving cardiovascular healthcare delivery. The scope and impact of his work support consideration for recognition under the Innovative Research Award category.

Conclusion

Through extensive research in heart valve technologies, cardiovascular implants, and surgical innovation, Bart Meuris has contributed meaningful knowledge to the field of cardiovascular medicine. His combination of academic leadership, scientific productivity, and translational research impact positions him as a notable contributor to contemporary cardiac science and device development.

References

  1. Elsevier. (n.d.). Scopus author details: Bart Meuris, Author ID 6602378855. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=6602378855
  2. ORCID. (n.d.). Bart Meuris Research Profile.
    https://orcid.org/0000-0001-9176-293X
  3. Universitair Ziekenhuis Leuven. (2024). Department of Cardiovascular Sciences Employment Record.
  4. Meuris, B. et al. (2026). Factor XI inhibition with gruticibart prevents mechanical valve thrombosis in a porcine pulmonary model.
    DOI: https://doi.org/10.1016/j.bvth.2026.100168
  5. Meuris, B. et al. (2026). Sex-related outcome after sutureless aortic valve replacement with Perceval Plus.
    DOI: https://doi.org/10.1093/icvts/ivag170
  6. Meuris, B. et al. (2026). Rapid deployment valves: current position on the market and future directions.
    DOI: https://doi.org/10.1080/17434440.2026.2638363
  7. Meuris, B. et al. (2026). Hemodynamic performance and durability of transcatheter valves for native aortic valve stenosis.
    DOI: https://doi.org/10.1080/00015385.2025.2576449

Sandra Celina Fernandes Fonseca | Cardiology | Innovative Research Award

Published on by Cardiology and Cardiovascular Medicine

Innovative Research Award

Sandra Celina Fernandes Fonseca
University of Trás-os-Montes and Alto Douro
Sandra Celina Fernandes Fonseca
Affiliation University of Trás-os-Montes and Alto Douro
Country Portugal
Scopus ID 57191525441
Documents 23
Citations 85
h-index 5
Subject Area Cardiology
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID 0000-0001-9468-7269

The Innovative Research Award recognizes sustained scholarly contributions that advance evidence-based understanding in cardiovascular and health sciences. Sandra Celina Fernandes Fonseca, affiliated with the University of Trás-os-Montes and Alto Douro, has developed an interdisciplinary research portfolio examining exercise physiology, cardiovascular responses, athlete well-being, and health promotion across diverse populations. Her publication record demonstrates engagement with clinically relevant topics at the intersection of cardiology, physical activity, and preventive medicine.[1]

Abstract

Fonseca’s research addresses the physiological and behavioral determinants of cardiovascular health, with particular emphasis on exercise responses, athlete health, and lifestyle-related risk factors. Her work integrates observational and applied methodologies to evaluate how physical activity, motivation, sleep, and substance use influence cardiovascular outcomes and performance indicators.[2]

Keywords

Cardiology; exercise physiology; cardiovascular medicine; athlete health; physical activity; preventive health; sleep quality; sports science.

Introduction

Contemporary cardiovascular research increasingly recognizes the importance of behavioral and environmental determinants of health. Fonseca’s investigations contribute to this perspective by examining how exercise intensity, perceived exertion, nutrition, and psychosocial variables affect cardiovascular adaptation and well-being across athletic and general populations.[3]

Research Profile

According to indexed author records, Fonseca has authored or co-authored 23 Scopus-indexed documents with 85 citations and an h-index of 5. Her scholarship spans cardiology, sports medicine, public health, and kinesiology, reflecting a multidisciplinary approach to cardiovascular prevention and health promotion.[1]

Research Contributions

  • Assessment of cardiovascular responses to exercise under varying behavioral conditions, including alcohol consumption.
  • Investigation of sleep quality, motivation, and mental health among Paralympic athletes.
  • Evaluation of caffeine-related effects on glycaemia and blood pressure in combat sports participants.
  • Analysis of physical activity patterns and self-rated health during the COVID-19 pandemic.

Publications

Selected publications include studies in Nutrients, Sports, Turkish Journal of Kinesiology, and O Mundo da Saúde. Notable recent works examine cardiovascular responses to exercise and alcohol interaction and predictive factors associated with athlete mental health during social isolation.[4]

Research Impact

The practical implications of Fonseca’s work extend to exercise prescription, athlete monitoring, and preventive cardiovascular care. By integrating physiological measures with behavioral indicators, her studies support more comprehensive approaches to health promotion and performance optimization.[5]

Award Suitability

Fonseca’s multidisciplinary output aligns with the objectives of the International Research Awards on Cardiology & Cardiovascular Medicine. Her emphasis on translational research, preventive health strategies, and evidence-informed interventions demonstrates relevance to current priorities in cardiovascular science and population health.[6]

Conclusion

Sandra Celina Fernandes Fonseca has established a coherent research agenda centered on exercise-related cardiovascular outcomes and health behavior. Her scholarly contributions provide meaningful insights for clinicians, researchers, and public health practitioners seeking to improve cardiovascular well-being through lifestyle-based interventions.

References

  1. Elsevier. (n.d.). Scopus author details: Sandra Celina Fernandes Fonseca, Author ID 57191525441. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57191525441
  2. Fonseca, S. C. F., et al. (2026). Cardiovascular Response to Exercise with and Without Alcohol Consumption. Nutrients.
    DOI: https://doi.org/10.3390/nu18091407
  3. Fonseca, S. C. F., et al. (2026). Predictive Factors of Mental Health in Athletes from the Paralympic Preparation Program During Social Isolation. Sports.
    DOI: https://doi.org/10.3390/sports14040160
  4. Fonseca, S. C. F., et al. (2025). Effects of caffeine on glycaemia and blood pressure in women practising Muay Thai. Turkish Journal of Kinesiology.
    DOI: https://doi.org/10.31459/turkjkin.1704368
  5. Fonseca, S. C. F., et al. (2025). Physical activity practice and negative self-rated health among university students during COVID-19. O Mundo da Saúde.
    DOI: https://doi.org/10.15343/0104-7809.202549e17082025I
  6. Pencis. (n.d.). International Research Awards on Cardiology & Cardiovascular Medicine.
    cardiology-conferences.pencis.com

Robert Guidoin | Cardiac Devices and Implants | Innovative Research Award

Published on by Cardiology and Cardiovascular Medicine

Innovative Research Award

Robert Guidoin
Laval University, Canada
Robert Guidoin
Affiliation Laval University
Country Canada
Scopus ID 7103350756
Documents 471
Citations 7,182
h-index 39
Subject Area Cardiac Devices and Implants
Event International Research Awards on Cardiology & Cardiovascular Medicine

The Innovative Research Award recognizes sustained scholarly contributions that have advanced the understanding, development, and clinical application of cardiovascular technologies. Robert Guidoin of Laval University has established a significant body of work in biomaterials, membrane oxygenators, vascular prostheses, and blood–device interactions, with particular emphasis on the performance and thrombogenicity of implantable cardiac devices. His publication record, citation impact, and long-term influence within cardiovascular engineering position him as a noteworthy candidate for recognition by the International Research Awards on Cardiology & Cardiovascular Medicine.[1]

Abstract

This article evaluates the academic achievements of Robert Guidoin in relation to the Innovative Research Award. His investigations into membrane oxygenators, blood-compatible materials, and implantable cardiovascular devices contributed to foundational knowledge in cardiac biomaterials research. Through interdisciplinary collaborations spanning engineering, surgery, and experimental medicine, his work supported improvements in device safety and clinical outcomes.[2]

Keywords

Cardiac devices; biomaterials; membrane oxygenators; thrombogenicity; cardiovascular engineering; vascular implants; blood compatibility; translational research.

Introduction

Advances in cardiovascular medicine increasingly rely on durable, biocompatible devices capable of minimizing adverse blood interactions. During the formative years of cardiovascular biomaterials research, Guidoin contributed to investigations that examined how artificial surfaces behave during extracorporeal circulation and long-term implantation.[3]

Research Profile

According to Scopus metrics, Guidoin has authored 471 indexed documents, received 7,182 citations, and achieved an h-index of 39. His scholarly activity demonstrates consistent engagement with cardiovascular devices, biomaterial characterization, and translational engineering applications. The breadth of his collaborations reflects a sustained commitment to multidisciplinary innovation.[1]

Research Contributions

  • Investigated blood-surface interactions using scanning electron microscopy to characterize biomaterial performance.
  • Evaluated the anti-thrombogenic properties of polyproteic membranes in vivo.
  • Contributed to studies of heparin metabolism relevant to extracorporeal circulation.
  • Advanced understanding of deposits and degradation mechanisms in membrane oxygenators.[4]

Publications

Selected early publications demonstrate a coherent research trajectory focused on cardiovascular support technologies and biomaterial evaluation. These studies established methodologies that informed subsequent investigations into implant performance and blood compatibility.[5]

Research Impact

The influence of Guidoin’s work extends across biomedical engineering, cardiovascular surgery, and medical device development. Citation indicators suggest enduring relevance, while his investigations helped establish evidence-based approaches for assessing device thrombogenicity and material compatibility. These contributions continue to inform contemporary cardiovascular implant design.[1][6]

Award Suitability

The Innovative Research Award emphasizes originality, measurable impact, and contributions that advance cardiovascular medicine. Guidoin’s publication output, translational focus, and longstanding influence within cardiac device research align with these criteria. His work exemplifies how interdisciplinary science can bridge experimental investigation and clinical application.

Conclusion

Robert Guidoin’s research legacy reflects sustained excellence in cardiovascular biomaterials and implant science. His contributions to understanding blood-device interactions and oxygenator performance have provided a valuable foundation for subsequent innovations in cardiac technology. On the basis of scholarly productivity, citation impact, and translational significance, he represents a strong candidate for recognition through the Innovative Research Award.

References

  1. Elsevier. (n.d.). Scopus author details: Robert Guidoin, Author ID 7103350756. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7103350756
  2. Guidoin, R., & Awad, J. (1974). Scanning electron microscopy study of the immediate blood-surface interaction on membranes for oxygenators.
  3. Guidoin, R., Sirois, M., Awad, J., & Rousseau, C. (1974). Vitesse de métabolisation de l’héparine chez le chien.
  4. Guidoin, R., Awad, J., Brassard, A., Domurado, D., Broun, G., & Thomas, D. (1974). Anti-thrombogenicity of polyproteic membranes: in vivo evaluation.
  5. Awad, J., Lupien, P., Brassard, A., Guidoin, R., & Morin, P. (1974). Biologic studies with a membrane oxygenator during prolonged arteriovenous bypass.
  6. Guidoin, R., Awad, J., Laperche, Y., & Morin, P. (1975). Nature of deposits in a membrane oxygenator after extracorporeal circulation: A SEM study.

Xiaowei Xue | Environmental Epidemiology | Innovative Research Award

Published on by Cardiology and Cardiovascular Medicine

Innovative Research Award

Xiaowei Xue
Fudan University, China
Xiaowei Xue
Affiliation Fudan University
Country China
Scopus ID 57314141000
Documents 24
Citations 742
h-index 12
Subject Area Environmental Epidemiology
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID 0009-0009-3761-1773

Xiaowei Xue is a researcher at Fudan University whose work lies at the intersection of environmental epidemiology and cardiovascular health. Through large-scale population studies, longitudinal monitoring, and exposure assessment research, the researcher has examined how air pollution, temperature variability, and environmental risk factors influence cardiovascular outcomes. The scholarly record reflects a sustained focus on hypertension, arterial stiffness, heart rate variability, and preventive public health strategies, contributing valuable evidence to contemporary cardiovascular and environmental health research.[1]

Abstract

The research portfolio of Xiaowei Xue focuses on understanding environmental determinants of cardiovascular disease and population health. Recent investigations have examined associations between air pollution exposure, blood pressure regulation, arterial stiffness, heart rate variability, and mortality from hypertension-related complications. By combining epidemiological methods with advanced exposure assessment techniques, the researcher has contributed evidence supporting preventive approaches to cardiovascular risk reduction and environmental health policy development.[2]

Keywords

  • Environmental Epidemiology
  • Hypertension
  • Air Pollution
  • Cardiovascular Health
  • Arterial Stiffness
  • Public Health Research

Introduction

Environmental exposures are increasingly recognized as important contributors to cardiovascular morbidity and mortality. Research addressing pollution, climate-related variables, and physiological responses provides valuable insights into disease prevention. Xiaowei Xue has contributed to this field through studies evaluating the cardiovascular effects of particulate matter, temperature fluctuations, and air purification interventions in diverse populations.[3]

Research Profile

The researcher has accumulated 742 citations and an h-index of 12, demonstrating notable scholarly influence within environmental epidemiology and cardiovascular research.[1] Publications appear in leading journals including the Journal of the American College of Cardiology, Environmental Pollution, and Environmental Science & Technology. The research profile highlights expertise in population-level cardiovascular risk assessment and environmental exposure science.

Research Contributions

A major contribution includes a case-crossover study involving approximately 2.1 million deaths in China, which investigated short-term air pollution exposure and mortality from hypertension and associated multiorgan complications.[2] Additional studies explored how fine particulate matter may influence arterial stiffness through inflammatory pathways and how outdoor temperature affects ambulatory blood pressure patterns.[3] The researcher has also examined cardiovascular benefits of air purification among children through randomized clinical investigation and evaluated temperature-related effects on heart rate variability using longitudinal panel data. These studies contribute to understanding environmental interventions capable of supporting cardiovascular health protection.[4]

Publications

  1. Short-Term Exposure to Air Pollution Increases Mortality From Hypertension and its Multiorgan Complications. DOI
  2. Short-term Exposure to Fine Particulate Matter and Arterial Stiffness. DOI
  3. Cardiovascular Benefits of Air Purification in Children. DOI

Research Impact

The impact of Xiaowei Xue’s research extends across cardiovascular epidemiology, environmental medicine, and public health. Findings have strengthened understanding of how environmental exposures contribute to cardiovascular risk and have provided evidence relevant to health policy, pollution control strategies, and preventive medicine initiatives.[5]

Award Suitability

Xiaowei Xue demonstrates strong suitability for the Innovative Research Award through impactful investigations connecting environmental exposures with cardiovascular outcomes. The combination of high citation performance, interdisciplinary methodology, and contributions to population health research aligns closely with the objectives of the International Research Awards on Cardiology & Cardiovascular Medicine.[1]

Conclusion

Through investigations of air pollution, temperature exposure, blood pressure regulation, and cardiovascular prevention strategies, Xiaowei Xue has contributed meaningful evidence to environmental epidemiology and cardiovascular medicine. The researcher’s work supports a broader understanding of environmental determinants of health and their implications for disease prevention and public health advancement.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Xiaowei Xue, Author ID 57314141000. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57314141000
  2. Xue, X., et al. (2026). Short-Term Exposure to Air Pollution Increases Mortality From Hypertension and its Multiorgan Complications.
    https://doi.org/10.1016/j.jacc.2026.01.006
  3. He, X., et al. (2026). Short-term Exposure to Fine Particulate Matter and its Chemical Constituents May Affect Arterial Stiffness.
    https://doi.org/10.1016/j.envpol.2026.127735
  4. Xue, X., et al. (2025). Cardiovascular Benefits of Air Purification in Children.
    https://doi.org/10.1021/acs.est.5c06712
  5. Hu, J., et al. (2025). Attending to the Effects of Outdoor Temperature on Blood Pressure.
    https://doi.org/10.1016/j.envpol.2025.126301

Isa Ardahanli | Hypertension | Research Excellence Award

Published on by Cardiology and Cardiovascular Medicine

Research Excellence Award

Isa Ardahanli
Bilecik Şeyh Edebali University, Turkey
Isa Ardahanli
Affiliation Bilecik Şeyh Edebali University
Country Turkey
Scopus ID 56520257000
Documents 35
Citations 144
h-index 7
Subject Area Hypertension
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID
0000-0002-9309-803X

Isa Ardahanli is a researcher affiliated with Bilecik Şeyh Edebali University whose academic work focuses on hypertension, cardiovascular medicine, pharmacological interactions, and translational clinical research. The researcher has contributed to publications addressing aortic stiffness, antiplatelet therapy, heart failure management, and cardiovascular complications associated with pharmacological interventions. The scholarly profile demonstrates interdisciplinary engagement in cardiovascular sciences and clinical medicine with growing citation impact in peer-reviewed research.[1]

Abstract

The research activities of Isa Ardahanli involve cardiovascular medicine, hypertension management, pharmacological safety, and diagnostic assessment methodologies. Published studies and commentaries have explored aortic stiffness in subclinical hypothyroidism, dual antiplatelet therapy in coronary artery disease, and comparative therapeutic strategies in heart failure management. The researcher has also contributed to interdisciplinary investigations integrating artificial intelligence and spectrochemical analysis for critically ill patient assessment. These contributions reflect ongoing involvement in clinically relevant cardiovascular and translational research.[2]

Keywords

  • Hypertension
  • Cardiovascular Medicine
  • Heart Failure
  • Aortic Stiffness
  • Clinical Pharmacology
  • Artificial Intelligence in Medicine

Introduction

Cardiovascular research continues to emphasize the importance of diagnostic precision, pharmacological safety, and evidence-based therapeutic strategies. Studies addressing hypertension, antiplatelet therapy, and heart failure management are central to improving patient outcomes and reducing cardiovascular risk. Isa Ardahanli has contributed to these research areas through scholarly commentaries, collaborative investigations, and publications focused on cardiovascular pharmacology and clinical assessment techniques.[3]

Research Profile

According to available Scopus metrics, Isa Ardahanli has achieved 144 citations and an h-index of 7, indicating recognized scholarly engagement within cardiovascular medicine and hypertension research.[1] The publication record includes contributions to journals such as Acta Cardiologica, Talanta, and Arquivos Brasileiros de Cardiologia. Research themes include cardiovascular therapeutics, diagnostic methods, and interdisciplinary medical technologies.

Research Contributions

A notable contribution involves commentary on non-invasive oscillometric approaches for evaluating aortic stiffness in patients with subclinical hypothyroidism. This work discusses diagnostic methodologies relevant to cardiovascular risk stratification and vascular assessment.[2] The researcher has also participated in studies examining dual antiplatelet therapy among Turkish patients with coronary artery disease and analyses of therapeutic strategies in heart failure management. Additional interdisciplinary work integrated explainable artificial intelligence and spectrochemical methods to evaluate critically ill patients with COVID-19, demonstrating broader translational research engagement.[4]

Publications

  1. Commentary on the Role of Non-invasive Oscillometric Methods in Assessing Aortic Stiffness.
    DOI Link
  2. Fixed-Dose Antiplatelet Dual Combination in Patients with Coronary Artery Disease.
    DOI Link
  3. Spectrochemical and Explainable Artificial Intelligence Approaches for Critically Ill Patients with COVID-19.
    DOI Link

Research Impact

The researcher’s publications contribute to discussions concerning cardiovascular risk management, therapeutic optimization, and innovative diagnostic methodologies. Collaborative studies addressing hypertension and cardiovascular pharmacology support evidence-based clinical practice and ongoing advancements in cardiovascular medicine.[5]

Award Suitability

Isa Ardahanli demonstrates suitability for the Research Excellence Award through contributions to hypertension research, cardiovascular therapeutics, and interdisciplinary clinical investigations. The publication record, citation performance, and engagement in cardiovascular-focused studies align with the objectives of the International Research Awards on Cardiology & Cardiovascular Medicine.[3]

Conclusion

Isa Ardahanli has contributed to cardiovascular medicine through research involving hypertension, vascular assessment, pharmacological evaluation, and translational healthcare technologies. The researcher’s interdisciplinary publications provide clinically relevant insights that support diagnostic innovation and evidence-based cardiovascular practice within contemporary medical research.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Isa Ardahanli, Author ID 56520257000. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56520257000
  2. Aslan, R., et al. (2026). Commentary on the Role of Non-invasive Oscillometric Methods in Assessing Aortic Stiffness in Subclinical Hypothyroidism.
    https://doi.org/10.1080/00015385.2025.2453800
  3. Aslan, R., et al. (2025). Comparative Effectiveness of Torsemide and Furosemide in Heart Failure.
    https://doi.org/10.1080/00015385.2025.2476890
  4. Tokgoz, G., et al. (2024). Spectrochemical and Explainable Artificial Intelligence Approaches for Molecular Identification in Critically Ill Patients.
    https://doi.org/10.1016/j.talanta.2024.126652
  5. Oz, A., et al. (2024). Fixed-Dose Antiplatelet Dual Combination in Patients with Coronary Artery Disease in Turkish Population.
    https://doi.org/10.36660/ABC.20240202I